562 related articles for article (PubMed ID: 31683723)
41. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
[TBL] [Abstract][Full Text] [Related]
42. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer.
Huang CY; Chiang SF; Ke TW; Chen TW; You YS; Chen WT; Chao KSC
Sci Rep; 2018 Oct; 8(1):15658. PubMed ID: 30353144
[TBL] [Abstract][Full Text] [Related]
44. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Wang JL; Yu T; Sun TT; Feng Y; Xiong H; Fang JY
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337839
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
48. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
49. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
50. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
52. Classification of gallbladder cancer by assessment of CD8
Lin J; Long J; Wan X; Chen J; Bai Y; Wang A; Yang X; Wu Y; Robson SC; Sang X; Zhao H
BMC Cancer; 2018 Jul; 18(1):766. PubMed ID: 30055582
[TBL] [Abstract][Full Text] [Related]
53. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
55. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
[TBL] [Abstract][Full Text] [Related]
56. Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.
Kim MH; Jang M; Kim H; Lee WJ; Kang CM; Choi HJ
Cancer Immunol Immunother; 2019 Mar; 68(3):443-454. PubMed ID: 30604042
[TBL] [Abstract][Full Text] [Related]
57. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
59. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
[TBL] [Abstract][Full Text] [Related]
60. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]